title: Combination dermatological products: a comparison of betamethasone dipropionate/clotrimazole/gentamicin sulphate and flumethasone pivalate/clioquinol creams.
abstract: The combination creams, betamethasone dipropionate/clotrimazole/gentamicin sulphate and flumethasone pivalate/clioquinol, were compared in patients with corticosteroid responsive dermatoses and/or cutaneous fungal and/or bacterial infections. Medication was applied to affected areas twice daily for 28 days. Of 67 patients enrolled, 31 treated with betamethasone/clotrimazole/gentamicin and 33 given flumethasone pivalate/clioquinol were evaluated for efficacy and safety each week during therapy and once 14 days post-therapy. Disease signs and symptoms were less severe in the group given betamethasone/clotrimazole/gentamicin than in the comparative group at days 7 (P = 0.04), 21 (P = 0.02), 28 (P = 0.09), and 42 (P = 0.09) and at patients' last valid visit (P = 0.06). By the last valid visit, signs/symptoms had improved by 82% for patients treated with betamethasone/clotrimazole/gentamicin versus 68% for those treated with flumethasone pivalate/clioquinol. Patients given betamethasone/clotrimazole/gentamicin had statistically significantly better therapeutic responses than those given flumethasone pivalate/clioquinol at day 7 and, by the last valid visit, 19/31 (61%) patients given betamethasone/clotrimazole/gentamicin compared to 15/33 (45%) given flumethasone pivalate/clioquinol had a complete cure or an excellent therapeutic response. Median time of onset of relief of erythema and pruritus was approximately 2 days, regardless of treatment. No adverse reactions were reported.
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D007464:Clioquinol / Q000008:administration & dosage / Q000627:therapeutic use; D003022:Clotrimazole / Q000008:administration & dosage / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005443:Flumethasone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012871:Skin Diseases / Q000188:drug therapy*; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D005839:Gentamicins; D005938:Glucocorticoids; C005565:flumethasone pivalate; D007464:Clioquinol; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D003022:Clotrimazole; D005443:Flumethasone